Ardelyx
Biopharmaceutical company focused on discovery, development, and commercialization of small-molecule therapies for gastrointestinal and kidney diseases. Operates a clinical pipeline spanning preclinical through approved products, conducts Phase 1–3 clinical trials (including pediatric studies), publishes clinical and real-world research, and provides patient support and access programs. Maintains compliance, governance, and partnership activities to support development and global commercialization.
Industries
Nr. of Employees
large (251-1000)
Patents
Hormone receptor modulators for treating metabolic conditions and disorders
US-12209088-B2
View DetailsCompounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US-12016856-B2
View Details
Hormone receptor modulators for treating metabolic conditions and disorders
US-12209088-B2
View DetailsCompounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US-12016856-B2
View DetailsProducts
IBSRELA (tenapanor)
Approved oral small-molecule therapy indicated for irritable bowel syndrome with constipation (IBS-C).
XPHOZAH (tenapanor)
Approved oral therapy for management of hyperphosphatemia in patients with chronic kidney disease on dialysis.
IBSRELA
Tenapanor approved for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) and in Phase III for Chronic Idiopathic Constipation (CIC).
IBSRELA (tenapanor)
Approved oral small-molecule therapy indicated for irritable bowel syndrome with constipation (IBS-C).
XPHOZAH (tenapanor)
Approved oral therapy for management of hyperphosphatemia in patients with chronic kidney disease on dialysis.
IBSRELA
Tenapanor approved for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) and in Phase III for Chronic Idiopathic Constipation (CIC).
Services
High-touch program providing patient access and affordability support with integration into medical office workflows and connectivity between patients and healthcare providers; includes phone support.
High-touch program providing patient access and affordability support with integration into medical office workflows and connectivity between patients and healthcare providers; includes phone support.
Expertise Areas
- Clinical trial management
- Gastrointestinal and nephrology therapeutics
- Drug discovery and preclinical development
- Regulatory compliance and submissions
Key Technologies
- NHE3 inhibition (small-molecule mechanism)
- Clinical trial methodologies (randomized, double-blind, placebo-controlled)
- Digital patient services platforms
- Formulation development and palatability testing
News & Updates
Company announcement regarding participation in investor conferences.
Quarterly financial results and business update.
Notice of upcoming financial results release.
Real-world survey study reporting treatment satisfaction with tenapanor in dialysis patients with hyperphosphatemia.
Post-hoc analysis of clinical trial data evaluating symptom relief in IBS-C.
Pilot randomized study assessing liquid formulation stability and palatability.
Company announcement regarding participation in investor conferences.
Quarterly financial results and business update.
Notice of upcoming financial results release.
Real-world survey study reporting treatment satisfaction with tenapanor in dialysis patients with hyperphosphatemia.
Post-hoc analysis of clinical trial data evaluating symptom relief in IBS-C.
Pilot randomized study assessing liquid formulation stability and palatability.